Browse SLC9B2

Summary
SymbolSLC9B2
Namesolute carrier family 9, subfamily B (NHA2, cation proton antiporter 2), member 2
Aliases FLJ23984; NHA2; NHEDC2; Na+/H+ exchanger domain containing 2; solute carrier family 9, subfamily B (cation p ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein Mitochondrion membrane Multi-pass membrane protein Endosome membrane Multi-pass membrane protein Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane Multi-pass membrane protein Cell projection, cilium, flagellum membrane Multi-pass membrane protein Basolateral cell membrane Multi-pass membrane protein Apical cell membrane Multi-pass membrane protein Note=Strong colocalization with LAMP1 and TCIRG1 in osteoclasts. In beta-cells colocalizes with RAB4A and SYP. Localizes to the basolateral membrane of polarized osteoclasts.
Domain PF00999 Sodium/hydrogen exchanger family
Function

Na(+)/H(+) antiporter that extrudes Na(+) or Li(+) in exchange for external protons across the membrane (PubMed:18000046, PubMed:28154142, PubMed:22948142, PubMed:18508966). Contributes to the regulation of intracellular pH, sodium homeostasis, and cell volume. Plays an important role for insulin secretion and clathrin-mediated endocytosis in beta-cells (By similarity). Involved in sperm motility and fertility (By similarity). It is controversial whether SLC9B2 plays a role in osteoclast differentiation or not (By similarity).

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0002761 regulation of myeloid leukocyte differentiation
GO:0002763 positive regulation of myeloid leukocyte differentiation
GO:0006814 sodium ion transport
GO:0006818 hydrogen transport
GO:0010720 positive regulation of cell development
GO:0015672 monovalent inorganic cation transport
GO:0015992 proton transport
GO:0030099 myeloid cell differentiation
GO:0030316 osteoclast differentiation
GO:0036035 osteoclast development
GO:0045637 regulation of myeloid cell differentiation
GO:0045639 positive regulation of myeloid cell differentiation
GO:0045670 regulation of osteoclast differentiation
GO:0045672 positive regulation of osteoclast differentiation
GO:0060348 bone development
GO:0061515 myeloid cell development
GO:0098751 bone cell development
GO:1902105 regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1902600 hydrogen ion transmembrane transport
GO:1903010 regulation of bone development
GO:1903012 positive regulation of bone development
GO:1903706 regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
GO:2001204 regulation of osteoclast development
GO:2001206 positive regulation of osteoclast development
Molecular Function GO:0005451 monovalent cation:proton antiporter activity
GO:0015077 monovalent inorganic cation transmembrane transporter activity
GO:0015078 hydrogen ion transmembrane transporter activity
GO:0015291 secondary active transmembrane transporter activity
GO:0015297 antiporter activity
GO:0015298 solute:cation antiporter activity
GO:0015299 solute:proton antiporter activity
GO:0015491 cation:cation antiporter activity
GO:0022804 active transmembrane transporter activity
GO:0099516 ion antiporter activity
Cellular Component GO:0005743 mitochondrial inner membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-983712: Ion channel transport
R-HSA-2672351: Stimuli-sensing channels
R-HSA-382551: Transmembrane transport of small molecules
Summary
SymbolSLC9B2
Namesolute carrier family 9, subfamily B (NHA2, cation proton antiporter 2), member 2
Aliases FLJ23984; NHA2; NHEDC2; Na+/H+ exchanger domain containing 2; solute carrier family 9, subfamily B (cation p ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SLC9B2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSLC9B2
Namesolute carrier family 9, subfamily B (NHA2, cation proton antiporter 2), member 2
Aliases FLJ23984; NHA2; NHEDC2; Na+/H+ exchanger domain containing 2; solute carrier family 9, subfamily B (cation p ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SLC9B2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSLC9B2
Namesolute carrier family 9, subfamily B (NHA2, cation proton antiporter 2), member 2
Aliases FLJ23984; NHA2; NHEDC2; Na+/H+ exchanger domain containing 2; solute carrier family 9, subfamily B (cation p ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SLC9B2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0450.909
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5720.6
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3440.67
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.0590.0141
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.3550.327
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6860.682
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3790.429
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3460.778
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3590.778
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1270.872
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1360.902
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0740.551
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SLC9B2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSLC9B2
Namesolute carrier family 9, subfamily B (NHA2, cation proton antiporter 2), member 2
Aliases FLJ23984; NHA2; NHEDC2; Na+/H+ exchanger domain containing 2; solute carrier family 9, subfamily B (cation p ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC9B2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSLC9B2
Namesolute carrier family 9, subfamily B (NHA2, cation proton antiporter 2), member 2
Aliases FLJ23984; NHA2; NHEDC2; Na+/H+ exchanger domain containing 2; solute carrier family 9, subfamily B (cation p ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC9B2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC9B2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSLC9B2
Namesolute carrier family 9, subfamily B (NHA2, cation proton antiporter 2), member 2
Aliases FLJ23984; NHA2; NHEDC2; Na+/H+ exchanger domain containing 2; solute carrier family 9, subfamily B (cation p ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC9B2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSLC9B2
Namesolute carrier family 9, subfamily B (NHA2, cation proton antiporter 2), member 2
Aliases FLJ23984; NHA2; NHEDC2; Na+/H+ exchanger domain containing 2; solute carrier family 9, subfamily B (cation p ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SLC9B2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSLC9B2
Namesolute carrier family 9, subfamily B (NHA2, cation proton antiporter 2), member 2
Aliases FLJ23984; NHA2; NHEDC2; Na+/H+ exchanger domain containing 2; solute carrier family 9, subfamily B (cation p ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SLC9B2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSLC9B2
Namesolute carrier family 9, subfamily B (NHA2, cation proton antiporter 2), member 2
Aliases FLJ23984; NHA2; NHEDC2; Na+/H+ exchanger domain containing 2; solute carrier family 9, subfamily B (cation p ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SLC9B2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.